The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
General Updates | How can we improve the cost-effectiveness of AML treatment?
Jan Philipp Bewersdorf, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, discusses the importance of exploring strategies to improve the cost-effectiveness of acute myeloid leukemia (AML) treatment. Improving the cost of targeted therapies will require collaboration between physicians, the pharmaceutical industry, the government, and others. This interview was recorded virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
